Back to search

Democritus University of Thrace (DUTH)

Η ελεύθερη τριϊδωθυρονίνη (FT3) ορού ως δείκτης φλεγμονής σε ασθενείς υπό χρόνια αιμοκάθαρση: συσχέτιση των επιπέδων της στον ορό με τα αντίστοιχα επίπεδα της CRP και της IL-6

Abstract

dc:description

A number of recent studies have postulated that end stage renal disease patients receiving hemodialysis as a treatment can serve as a unique model of non-thyroidal illness syndrome. In reverse, it has been suggested that disarrangements in thyroid function can have a prognostic impact in hemodialysis patient’s survival. Indeed, recent studies have proposed a possible link between freeT3 and inflammation in hemodialysis, while other investigators postulated a connection between low freeT3 and the cardiorenal syndrome. The main pathogenetic mechanisms of non thyroidal illness syndrome in chronic inflammation, including end stage renal disease patients, seem to involve iodine retention, alterations to protein binding, derangements to deiodinases activity and dysregulation at the hypothalamic level, although most of them are still unclear. More recent studies gave evidence that the NTIS is an acute phase response, yielded by activation of a cytokine network. In such studies, interleukin-6, among others, inversely correlated with serum T3 levels. On the other hand, there are well established markers of inflammation, like CRP and IL-6, which have been closely linked with survival in ESRD patients. One well examined model of action is the high energy waste along with chronic inflammation and atheromatosis that hemodialysis patients are prone to. Moreover, recent studies focus on the low-grade inflammation, a common feature of the uremic environment. So it seems rather appealing to investigate these common pathways and prove a possible causality between low T3 syndrome and chronic inflammation in ESRD patients. Until the design of the present thesis, there were only few studies dealing with the search of a possible relationship between low freeT3 and chronic inflammation state in the uremic environment or its use as a prognostic marker for hemodialysis patients.Thus, the aim of this study was to explore a probable relationship between freeT3 and chronic low grade inflammation in a population of ESRD patients undergoing hemodialysis in Northern Greece, which encompasses several distinguishable features in terms of environmental and genotype characteristics, while also the diversity of treatment conditions. We examined the possible consequences of low freeT3 not as metabolic derangement in hemodialysis patients but as part of the puzzle of chronic low grade inflammation that outlines the uremic environment, through the rationale and mechanisms of low T3 or non thyroidal illness syndrome. Our thesis focused in the potent relationship of freeT3 with two established biomarkers of chronic inflammation, namely hsCRP and IL-6. Furthermore, as chronic inflammation seems to correlate independently with survival in ESRD patients treated with hemodialysis, we also prospectively examined a potential association of low plasma freeT3 with survival, while also with the incidence of new cardiovascular disease events. 117 patients consecutively entered the study with a total duration of 84 months. Among them 86 were male and 31 female patients with a mean age of 62.29±14.35 years. The sum of the patients received treatment in two large hemodialysis centers in Northern Greece, the Hemodialysis Unit of University Hospital in Alexandroupolis and the Hemodialysis Unit of “G.Papanikolaou” General District Hospital. All patients had been stabilized on renal replacement therapy for >3 months prior to enrollment (mean HD duration 113.4±65.1 months) and were clinically stable and free of active infection. Patients with known history of thyroid disorders or taking medications with possible effect in thyroid hormone values, like amiodarone or lithium, were excluded from the study.The sampling period involved three blood collections at the first of the month for three consecutive months in order to measure thyroid parameters (freeT3, freeT4 and TSH) and inflammatory markers, hsCRP and IL-6. At the same time, full blood count and biochemical parameters, like urea, creatinine, albumin and total protein, total cholesterol and triglycerides, were recorded from the monthly routine laboratory check of each patient. Adequacy of dialysis was calculated by the second generation Daugirdas equation of Kt/V and just for the first month. Anthropometric parameters like height, dry body weight and hence body mass index (BMI), were carefully recorded. In addition, we reviewed the medical files of each patient in order to record any history of hypertension, diabetes mellitus, smoking or cardiovascular disease. Blood pressure (BP) was measured in a supine position after 15 min of recumbency before a routine midweek dialysis session. Finally, hemodialysis (HD) modality, type of dialyzer, HD time and the type and status of vascular access, were also recorded. Serum thyroid parameters (free T3, freeT4, TSH), were measured by chemiluminescent, immunometric assays. Serum CRP levels were measured by high sensitivity nephelometry, while serum interleukin-6 (IL-6) concentrations were measured by sandwich ELISA immunoassay using commercially available standard kits.During follow up (81 months), deaths from all cause were recorded, while also the incidence of new CVD events. History of cardiovascular disease was defined as history of myocardial infarction, coronary artery bypass or clinical signs of angina pectoris, stroke or transient ischemic attack or peripheral vascular disease.In analyzing our results, we used two models of patient grouping. In the first model patients were dichotomized in groups of normal or low freeT3 based on our laboratory lower cut off value of 1.8 pg/mL. In the second model patients were divided in groups regarding the variation of freeT3 values during the three months of the sampling period. Four groups were formed, the one with patients having stable low freeT3 values, the second with patients that had stable normal values and the remaining two groups involved patients either with increases or decreases in the values of freeT3.Discussing our results, our data confirmed the high prevalence of low T3 syndrome among hemodialysis patients, which in our study was detected in 30% of the patients. Eventually, we only found a trend of correlation between freeT3 and inflammatory markers. More specific, bivariate analysis revealed significant correlations between hsCPR and freeT3 (Spearman’s rho= -0.323, p=0.001), TSH and freeT4 (Spearman’s rho= -0.259, p=0.010), and hsCRP and IL-6 (Spearman’s rho= 0.312, p=0.001). These associations remained significant in the following two months except from the correlation between hsCRP and freeT3. IL-6 did not seem to correlate with freeT3. Interestingly, serum albumin showed a strong correlation with freeT3, for April (Spearman's rho=0.3, p=0.001) and May (Spearman's rho=0.239, p=0.012), respectively. Finally, a linear statistically significant association between age and mean freeT3 was noted, which in our study population resulted in the following algorithm: Mean freeT3=2,80-0,01*Age.The basic demographic characteristics of the study population where typical of the Greek hemodialysis population according to the local registries.Regarding survival analysis, at least in the model where patients were dichotomized in low and normal freeT3 groups, low levels of freeT3 showed a clear survival deficit in hemodialysis patients [Kaplan-Meier, (log rank=6.3, p=0.002)]. Even in multivariate regression analysis with known confounders like age, DM, hypertension, hsCRP and creatinine, the presence of low freeT3 remained a significant, independent predictor of death among hemodialysis patients. However, in a multivariate stepwise Cox regression analysis, including also hemoglobin, dialysis vintage and history of CVD event, plasma freeT3 lost significance for prediction of all cause mortality. Indeed, in a fully adjusted model, factors independently associated with survival were age (3.2% higher odds of death for every year), history of CVD event (83.5% likelihood of death), dialysis vintage and hemoglobin. Moreover, for every 1g/dL of raise in hemoglobin there was a risk reduction for mortality of 43% and for every month a person was treated with hemodialysis there was a mild risk reduction of 0.9% for the overall 7-year mortality. The latter propably emerged due to a spurious relationship between freeT3 and HD vintage. In conclusion, in a study of patients on maintenance hemodialysis in Northern Greece, plasma freeT3 was not found to correlate strongly with two established markers of inflammation, namely hsCRP and IL-6. Assuming low freeT3 as part of non-thyroidal illness syndrome, while hsCRP and IL-6 as markers of low grade chronic inflammation in the uremic environment, no strong association was established. It is worth mentioning that not all previous studies that confirmed an association between low freeT3 and inflammation, actually used hsCRP, although it seems more sensitive in the detection of low grade chronic inflammation in ESRD.Nevertheless, in survival analysis low freeT3 emerged as an independent predictor of death, both in a univariate and a multivariate model.However, more prospective trials are required in the field of lowT3 syndrome among hemodialysis patients, in order to discuss potential therapeutic interventions or so as to adopt freeT3 as a strong prognostic marker for hemodialysis patients.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Fragkidis, Stylianos
  • Φραγκίδης, Στυλιανός

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/35691

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Fragkidis, Stylianos; Φραγκίδης, Στυλιανός. Η ελεύθερη τριϊδωθυρονίνη (FT3) ορού ως δείκτης φλεγμονής σε ασθενείς υπό χρόνια αιμοκάθαρση: συσχέτιση των επιπέδων της στον ορό με τα αντίστοιχα επίπεδα της CRP και της IL-6. Democritus University of Thrace (DUTH), 2015. http://hdl.handle.net/10442/hedi/35691